Contrasting Pulse Biosciences (PLSE) & The Competition

Pulse Biosciences (NASDAQ:PLSE) is one of 511 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it contrast to its competitors? We will compare Pulse Biosciences to related companies based on the strength of its analyst recommendations, valuation, earnings, dividends, profitability, institutional ownership and risk.

Insider and Institutional Ownership

76.9% of Pulse Biosciences shares are owned by institutional investors. Comparatively, 40.6% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 74.0% of Pulse Biosciences shares are owned by insiders. Comparatively, 15.0% of shares of all “Healthcare Equipment & Supplies” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Pulse Biosciences and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pulse Biosciences	-5,603.88%	-77.88%	-67.89%
Pulse Biosciences Competitors	-304.10%	-178.81%	-22.11%

Valuation & Earnings

This table compares Pulse Biosciences and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Pulse Biosciences	$1.49 million	-$72.78 million	-45.55
Pulse Biosciences Competitors	$1.89 billion	$136.85 million	12.52

Pulse Biosciences’ competitors have higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Pulse Biosciences and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulse Biosciences	1	0	5	1	2.86
Pulse Biosciences Competitors	4288	10570	18346	830	2.46

Pulse Biosciences presently has a consensus target price of $66.60, suggesting a potential upside of 20.83%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 21.17%. Given Pulse Biosciences’ competitors higher possible upside, analysts plainly believe Pulse Biosciences has less favorable growth aspects than its competitors.

Volatility & Risk

Pulse Biosciences has a beta of 1.65, suggesting that its share price is 65% more volatile than the S&P 500. Comparatively, Pulse Biosciences’ competitors have a beta of 2.57, suggesting that their average share price is 157% more volatile than the S&P 500.

Summary

Pulse Biosciences competitors beat Pulse Biosciences on 7 of the 13 factors compared.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc. develops medical devices using its proprietary nanosecond pulsed field ablation (nsPFA) technology. The technology delivers very short electrical pulses intended to disrupt targeted cells without relying on heat, with the goal of limiting effects on surrounding tissue. The company is developing nsPFA applications for cardiac electrophysiology and surgical oncology, including devices for tissue ablation. Its earlier CellFX System brought the technology to dermatology for treating certain benign skin lesions, marking an initial commercial application of the platform.